Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bioavailability and Neuroprotectivity of 3-(3, 4-dimethoxy phenyl)-1-4 (methoxy phenyl) prop-2-en-1-one against Schizophrenia: an in silico approach.

Journal of receptor and signal transduction research - 1 Jan 2000

Chintha Venkataramaiah, Wudayagiri Rajendra

Abstract excerpt

Schizophrenia is a major debilitating disorder worldwide. Schizophrenia is a result of multi-gene mutation and psycho-social factors. Mutated amino acid sequences in genes of DOPA such as TH, DDC, DBH, VMAT2, and NMDA (SET-1) have been implicated as major factors causing schizophrenia. In addition mutations in genes other than the DOPA genes such as RGS4, NRG1, COMT, AKT1 and DTNBP1 (SET 2) have also been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Availability
Share to Clozapine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Protein

Share to Dihydroxyphenylalanine

Share to Ketones

Share to Molecular Conformation

Share to N-Methylaspartate

Share to Plant Extracts

Source

Identifiers

PMID: 31829066
DOI: 10.1080/10799893.2019.1702689

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioavailability and Neuroprotectivity of 3-(3, 4-dimethoxy phenyl)-1-4 (methoxy phenyl) prop-2-en-1-one against Schizophrenia: an in silico approach.PMID 31829066Read ↗

[Approach for identifying novel drug targets of schizophrenia].Semantic proximity Read ↗

Pharmacoinformatics, Adaptive Evolution, and Elucidation of Six Novel Compounds for Schizophrenia Treatment by Targeting DAOA (G72) Isoforms.Semantic proximity Read ↗

Spondias mombin flavonoids showed super-binder ability with Downstream Molecular Targets of Parkinson’s Disease: Folkloric-therapy assessment as a Scaffold for Structural Studies in Neurodegenerative diseaseSemantic proximity Read ↗

The Clinical Antipsychotic Effect of Recently Developed Antipsychotic Drugs in SchizophreniaSemantic proximity Read ↗

Molecular insight into the mechanism of action of some beneficial flavonoids for the treatment of Parkinson’s DiseaseSemantic proximity Read ↗

Molecular docking of substituted pyrazolone analogs targeting MAO-B as therapeutic site for Parkinson: an in-silico studySemantic proximity Read ↗

In Silico Study Examining New Phenylpropanoids Targets with Antidepressant ActivitySemantic proximity Read ↗

In-Silico Identification of Drug Lead Molecule Against Pesticide Exposed-neurodevelopmental Disorders Through Network-Based Computational Model ApproachSemantic proximity Read ↗

Mechanisms of action of medicines for schizophrenia and bipolar illness: status and limitations.Semantic proximity Read ↗

Analysis and subsequent molecular docking of selected phytochemicals with SLC6A3 and SLC6A4 as potential therapeutic agents for Obsessive-Compulsive Disorder (OCD)Semantic proximity Read ↗

Virtual Screening of a Series of Phytocompounds from Lagenaria Siceraria for the Identification of Potential Antidiabetic Drug Candidates, in Silico Study and Drug Design ApproachesSemantic proximity Read ↗

Computational study of human tyrosine hydroxylase mutants to uphold [4-(Propan-2-yl) Phenyl]Carbamic acid as a potential inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.